These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 30591237)

  • 1. Pre-Nusinersen Hospitalization Costs of Children With Spinal Muscular Atrophy.
    Lee M; França UL; Graham RJ; McManus ML
    Pediatr Neurol; 2019 Mar; 92():3-5. PubMed ID: 30591237
    [No Abstract]   [Full Text] [Related]  

  • 2. Perspectives on Spinraza (Nusinersen) Treatment Study: Views of Individuals and Parents of Children Diagnosed with Spinal Muscular Atrophy.
    Pacione M; Siskind CE; Day JW; Tabor HK
    J Neuromuscul Dis; 2019; 6(1):119-131. PubMed ID: 30594933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.
    Zuluaga-Sanchez S; Teynor M; Knight C; Thompson R; Lundqvist T; Ekelund M; Forsmark A; Vickers AD; Lloyd A
    Pharmacoeconomics; 2019 Jun; 37(6):845-865. PubMed ID: 30714083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Technologies for the Treatment of Spinal Muscular Atrophy: A Systematic Review of Economic Studies.
    Motta-Santos A; Noronha K; Reis C; Freitas D; Carvalho L; Andrade M
    Value Health Reg Issues; 2024 Jul; 42():100985. PubMed ID: 38669792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides.
    Aartsma-Rus A
    Nucleic Acid Ther; 2017 Apr; 27(2):67-69. PubMed ID: 28346110
    [No Abstract]   [Full Text] [Related]  

  • 6. Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios.
    Broekhoff TF; Sweegers CCG; Krijkamp EM; Mantel-Teeuwisse AK; Leufkens HGM; Goettsch WG; Vreman RA
    Value Health; 2021 Jun; 24(6):759-769. PubMed ID: 34119073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent 'value for money' for the NHS? A rapid inquiry into suggestions that it may be cost-effective.
    Connock M; Andronis L; Auguste P; Dussart C; Armoiry X
    Expert Opin Biol Ther; 2020 Jul; 20(7):823-827. PubMed ID: 32434404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The End of the Beginning: The Journey to Molecular Therapies for Spinal Muscular Atrophy.
    Pacak CA; Kang PB
    Pediatr Neurol; 2020 Jan; 102():1-2. PubMed ID: 31481328
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-Effectiveness of Nusinersen and Universal Newborn Screening for Spinal Muscular Atrophy.
    Jalali A; Rothwell E; Botkin JR; Anderson RA; Butterfield RJ; Nelson RE
    J Pediatr; 2020 Dec; 227():274-280.e2. PubMed ID: 32659229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The health economics of cell and gene therapies.
    Beswick L
    Handb Clin Neurol; 2024; 205():155-167. PubMed ID: 39341653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spinal muscular atrophy: A modifiable disease emerges.
    Fitzgerald DA; Abel F; Jones KJ; Farrar MA
    Paediatr Respir Rev; 2018 Sep; 28():1-2. PubMed ID: 30414816
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical decision making around commercial use of gene and genetic therapies for spinal muscular atrophy.
    Waldrop MA
    Neurotherapeutics; 2024 Jul; 21(4):e00437. PubMed ID: 39241317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient characteristics and hospitalisation costs of spinal muscular atrophy in Spain: a retrospective multicentre database analysis.
    Darbà J; Marsà A
    BMJ Open; 2019 Nov; 9(11):e031271. PubMed ID: 31753879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethical Challenges Confronted When Providing Nusinersen Treatment for Spinal Muscular Atrophy.
    Burgart AM; Magnus D; Tabor HK; Paquette ED; Frader J; Glover JJ; Jackson BM; Harrison CH; Urion DK; Graham RJ; Brandsema JF; Feudtner C
    JAMA Pediatr; 2018 Feb; 172(2):188-192. PubMed ID: 29228163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps.
    Gidaro T; Servais L
    Dev Med Child Neurol; 2019 Jan; 61(1):19-24. PubMed ID: 30221755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Market access of Spinraza (Nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations.
    Simoens S; Huys I
    Gene Ther; 2017 Sep; 24(9):539-541. PubMed ID: 28880019
    [No Abstract]   [Full Text] [Related]  

  • 17. Direct Medical Costs of Spinal Muscular Atrophy in the Catalonia Region: A Population-Based Analysis.
    Darbà J
    Clin Drug Investig; 2020 Apr; 40(4):335-341. PubMed ID: 32144652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapy for spinomuscular atrophy: a biomedical advance, a missed opportunity for more equitable drug pricing.
    Friedmann T
    Gene Ther; 2017 Sep; 24(9):503-505. PubMed ID: 28639617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nusinersen in the Treatment of Spinal Muscular Atrophy.
    Goodkey K; Aslesh T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():69-76. PubMed ID: 30171535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comprehensive institutional overview of intrathecal nusinersen injections for spinal muscular atrophy.
    Mousa MA; Aria DJ; Schaefer CM; Kaye RD; Abruzzo TA; Bernes SM; Willard SD; Riemann MC; Towbin RB
    Pediatr Radiol; 2018 Nov; 48(12):1797-1805. PubMed ID: 30022258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.